Thermo Fisher Scientific (NYSE:TMO) Downgraded by DZ Bank to “Hold”

DZ Bank cut shares of Thermo Fisher Scientific (NYSE:TMO) from a strong-buy rating to a hold rating in a research note released on Friday morning,Zacks reports.

A number of other research analysts have also issued reports on the stock. Barclays raised their target price on shares of Thermo Fisher Scientific from $750.00 to $775.00 and gave the company an “overweight” rating in a research note on Thursday. Citigroup upped their price target on shares of Thermo Fisher Scientific from $685.00 to $800.00 and gave the company a “buy” rating in a report on Friday. UBS Group reaffirmed a “buy” rating and issued a $800.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday. Guggenheim started coverage on Thermo Fisher Scientific in a research note on Thursday, October 15th. They issued a “buy” rating on the stock. Finally, Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $681.00.

Thermo Fisher Scientific Stock Down 0.4%

Shares of TMO stock opened at $673.97 on Friday. The stock’s 50 day simple moving average is $645.72 and its 200 day simple moving average is $554.80. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.18 and a current ratio of 1.81. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $705.78. The company has a market capitalization of $249.20 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 2.81 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The firm had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the prior year, the business earned $5.79 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. As a group, research analysts predict that Thermo Fisher Scientific will post 25.20 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently bought and sold shares of the business. Strengthening Families & Communities LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock valued at $3,187,000 after purchasing an additional 21 shares in the last quarter. Bell Bank grew its position in shares of Thermo Fisher Scientific by 10.8% in the 3rd quarter. Bell Bank now owns 624 shares of the medical research company’s stock valued at $421,000 after purchasing an additional 61 shares during the period. 55 North Private Wealth LLC increased its stake in Thermo Fisher Scientific by 40.9% during the 3rd quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company’s stock worth $612,000 after purchasing an additional 263 shares in the last quarter. Jeppson Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $213,000. Finally, James Hambro & Partners LLP raised its holdings in Thermo Fisher Scientific by 0.8% during the 3rd quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company’s stock worth $156,260,000 after buying an additional 1,919 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Thermo Fisher reported adjusted earnings of $6.68 per share versus the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, topping estimates of $11.95 billion. TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
• Positive Sentiment: Analysts raised their valuation targets. TD Cowen increased its target to $810 and maintained a buy rating, while Stifel raised its target to $775 and Baird lifted its target to $756 with an outperform rating. These revisions imply meaningful upside from recent trading levels. TD Cowen analyst ratings
• Positive Sentiment: Improving end markets support the growth outlook. Investor commentary highlighted a broad-based recovery across life-science markets, including pharmaceutical demand, AI-related applications and other research tools. Erste Group also modestly raised its FY2027 EPS estimate to $27.58 from $27.51. Thermo Fisher benefits on broad-based recovery
• Neutral Sentiment: Secular market growth provides a longer-term tailwind. Industry forecasts call for strong expansion in next-generation sequencing kits and peptide synthesis, markets in which Thermo Fisher participates, although these reports do not directly change near-term earnings. NGS kits market forecast
• Negative Sentiment: Options activity signals caution. Heavy put-option buying indicates that some traders are hedging against, or positioning for, a pullback. The muted reaction to the earnings beat may also reflect elevated expectations and a relatively rich valuation. Thermo Fisher stock sees heavy put option buying

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.